| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 10/28/2004 | US20040213785 Stabilizedpreparations containing antibody |
| 10/28/2004 | US20040213778 a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer; used to elicit a humoral or cellular immune response; antibodies or T cells reactive used in active or passive immunization |
| 10/28/2004 | US20040213766 Compositions and methods for treating transplants |
| 10/28/2004 | US20040213759 Hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage; modification of various substrates, such as polypeptides, drugs and liposomes; upon cleavage of the linkage, the ligand |
| 10/28/2004 | US20040213756 Methods and compositions to treat myocardial conditions |
| 10/28/2004 | US20040213749 A dermal formulation for external use, contains sodium cromoglycate and a monoester of polyvalent alcohol and salicylic acid contained in a base; keeps skin healthy and demonstrates a sufficient effect in treating skin diseases |
| 10/28/2004 | US20040213745 Suitable for reconstitution and parenteral administration |
| 10/28/2004 | CA2811272A1 Pharmaceutical formulations containing methylnaltrexone |
| 10/28/2004 | CA2718356A1 High concentration antibody and protein formulations |
| 10/28/2004 | CA2527175A1 Remedies for diseases to be applied to eye |
| 10/28/2004 | CA2523864A1 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| 10/28/2004 | CA2522298A1 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 10/28/2004 | CA2522297A1 Process for making gel films |
| 10/28/2004 | CA2522296A1 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| 10/28/2004 | CA2522293A1 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom |
| 10/28/2004 | CA2522098A1 Absorption enhancers such as bht, bha or propylgallate |
| 10/28/2004 | CA2521979A1 Compositions and methods related to production of erythropoietin |
| 10/28/2004 | CA2521842A1 Phosphate derivatives of pharmaceutical products |
| 10/28/2004 | CA2521826A1 Recombinant il-9 antibodies and uses thereof |
| 10/28/2004 | CA2521464A1 Irna conjugates |
| 10/28/2004 | CA2521403A1 Macromolecules auto-assembled and photopolymerised around carbon nanotubes a method for production and application thereof |
| 10/28/2004 | CA2521381A1 Method for preparation of site-specific protein conjugates |
| 10/28/2004 | CA2521379A1 Pharmaceutical formulations containing methylnaltrexone |
| 10/28/2004 | CA2521361A1 Chrono delivery formulations and method of treating atrial fibrillation |
| 10/28/2004 | CA2521109A1 Anti-tumor vasculature effects of human serum albumin derivatives |
| 10/28/2004 | CA2517154A1 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives |
| 10/27/2004 | EP1471151A1 Improved method of producing lycopene through the fermentation of selected strains of blakeslea trispora, formulations and uses of the lycopene thus obtained |
| 10/27/2004 | EP1470826A1 Decoy-containing pharmaceutical compositions and method of using the same |
| 10/27/2004 | EP1470825A1 Reagents for detecting efavirenz |
| 10/27/2004 | EP1470824A1 Affinity proteins for controlled application of cosmetic substances |
| 10/27/2004 | EP1470816A2 Once-a-day metoprolol oral dosage form |
| 10/27/2004 | EP1470815A1 Opiod formulations for treating pain |
| 10/27/2004 | EP1470257A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470256A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE /GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470152A1 Peptides for increasing transfection efficiency |
| 10/27/2004 | EP1470146A2 Antibodies against the muc18 antigen |
| 10/27/2004 | EP1469989A2 Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
| 10/27/2004 | EP1469941A2 Microparticles and methods for their production |
| 10/27/2004 | EP1469938A1 Apparatus and process for preparing crystalline particles |
| 10/27/2004 | EP1469886A2 Pharmaceutical composition |
| 10/27/2004 | EP1469885A1 Parenteral composition of paracetamol |
| 10/27/2004 | EP1469876A2 Antimicrobial cationic peptides and formulations thereof |
| 10/27/2004 | EP1469848A1 Sedative non-benzodiazepine formulations |
| 10/27/2004 | EP1469840A1 Cyclosporin-containing sustained release pharmaceutical composition |
| 10/27/2004 | EP1469839A2 Transmucosal delivery of proton pump inhibitors |
| 10/27/2004 | EP1469838A1 Manufacture of oral dosage forms delivering both immediate release and sustained release drugs |
| 10/27/2004 | EP1469837A1 Bioadhesive composition comprising a polysaccharide and a polycarboxylated polymer |
| 10/27/2004 | EP1469836A1 Increased-dosage nelfinavir tablet and method of making same |
| 10/27/2004 | EP1469835A2 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 10/27/2004 | EP1469834A1 Multi-stage oral drug controlled-release system |
| 10/27/2004 | EP1469833A2 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| 10/27/2004 | EP1469832A1 Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
| 10/27/2004 | EP1469831A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
| 10/27/2004 | EP1469830A2 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| 10/27/2004 | EP1469829A2 Immediate release dosage forms containing solid drug dispersions |
| 10/27/2004 | EP1469828A2 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same |
| 10/27/2004 | EP1469827A2 Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
| 10/27/2004 | EP1469826A2 Osmotic delivery system |
| 10/27/2004 | EP1469813A2 Additives and products including oligoesters |
| 10/27/2004 | EP1469812A2 Oral insulin therapy |
| 10/27/2004 | EP1469811A2 Methods and compositions for oxygen transport comprising modified hemoglobin in plasma |
| 10/27/2004 | EP1469745A1 Use of multi-layer pigments in the food and pharmaceutical industry |
| 10/27/2004 | EP1469743A1 Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients |
| 10/27/2004 | EP1469732A1 Methods for preserving ophthalmic solutions and preserved ophtalmic solutions |
| 10/27/2004 | EP1416944A4 Composition for treatment of articular cartilage damage |
| 10/27/2004 | EP1387701B1 Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy |
| 10/27/2004 | EP1322275A4 Ultrasonic method and device for wound treatment |
| 10/27/2004 | EP1250050B1 Method and device for sanitation using bacteriophages |
| 10/27/2004 | EP1237578A4 Micro-cluster liquids and methods of making and using them |
| 10/27/2004 | EP1232188B1 Cyclodextrins substituted by fluoroalkyl groups, preparation and use thereof |
| 10/27/2004 | EP1212061B1 Injectable buprenorphine microparticle compositions and their use in reducing consumption of heroin and alcohol |
| 10/27/2004 | EP1204407B1 Implantable active ingredient depot |
| 10/27/2004 | EP1107793B1 Dextran-leptin conjugates, pharmaceutical compositions and related methods |
| 10/27/2004 | EP1107777B1 Stabilized pharmaceutical composition in lyophilized form |
| 10/27/2004 | EP1012603B1 Functional fragments of hiv-1 vpr protein and methods of using the same |
| 10/27/2004 | EP0998577B1 Conjugates of transporter peptides and nucleic acid analogs, and their use |
| 10/27/2004 | EP0832270B1 Cationic lipid:dna complexes for gene targeting |
| 10/27/2004 | EP0831791B1 Delivery of drugs to the lower gi tract |
| 10/27/2004 | CN1541226A Antibodes specific for CD44V6 |
| 10/27/2004 | CN1541129A Azeotrope-like compsns. of tetrafluoroethane, pentafluoropropane and water |
| 10/27/2004 | CN1541126A Microprojection array having beneficial agent contg coating |
| 10/27/2004 | CN1541114A Conjugates of macrocyclic metal complexes with biomolucules and utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy |
| 10/27/2004 | CN1541112A Percutaneous absorption preparations |
| 10/27/2004 | CN1541110A Methods for sterilizing prepns of monoclonal immunoglobulins |
| 10/27/2004 | CN1541109A Inhibitors of HER3 activity |
| 10/27/2004 | CN1541092A Method for treating primary insomnia |
| 10/27/2004 | CN1541091A Pharmaceutical prepn. in form of suspension comprising acid-labile active ingredient |
| 10/27/2004 | CN1541090A Prepn. of sustained release pharmaceutical compsn. |
| 10/27/2004 | CN1539499A Combination of stable interferon for lacal use |
| 10/27/2004 | CN1539421A Aciclovir compsns. contg. dimethicone |
| 10/27/2004 | CN1539398A Method for preparing base oil for cosmetic |
| 10/27/2004 | CN1172674C Penetration enhancing and irritation reducing systems |
| 10/27/2004 | CN1172671C Medicial composition for oral administration |
| 10/27/2004 | CN1172670C Liposome compositions for improved drugretention |
| 10/27/2004 | CN1172662C Coating agent for treating tinea and eczema |
| 10/27/2004 | CN1172658C Protein formulations |
| 10/27/2004 | CN1172656C Increasing agent for fregrance spreading rate and lasting property and increasing method thereof |
| 10/27/2004 | CN1172649C Process for the manufacture of liquid filled capsules |
| 10/26/2004 | US6809184 Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| 10/26/2004 | US6809182 Utlizing the varicella-zoster virus protein's ability to enter and exit eukaryotic cells for drug or secreting agent delivery |